Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.
J Am Assoc Nurse Pract
; 34(7): 918-923, 2022 Jul 01.
Article
em En
| MEDLINE
| ID: mdl-35580282
ABSTRACT
ABSTRACT The FDA recently approved a unique treatment regimen for management of HIV-1 infection in adults. A one-time per month injection of cabotegravir/rilpivirine can replace a current, stable antiretroviral regimen in those with virologic suppression, without history of treatment failure, or known or suspected resistance with cabotegravir or rilpivirine. A one-month oral trial should be initiated before switching to the extended-release injectable formulation. Cabotegravir/rilpivirine showed continued virologic suppression without clinically relevant changes in CD4+ cell counts. Clinicians should understand this new HIV regimen, its indications and suitability for select patients, administration and dosing, interactions, and most reported adverse events.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Fármacos Anti-HIV
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article